Cover Image
市場調查報告書

克隆氏症 - 開發中產品分析

Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232862
出版日期 內容資訊 英文 442 Pages
訂單完成後即時交付
價格
Back to Top
克隆氏症 - 開發中產品分析 Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2016
出版日期: 2016年08月10日 內容資訊: 英文 442 Pages
簡介

克隆氏症是消化管內壁發炎的疾病,不同的人病變部位也不一樣。主要的症狀有腹瀉、血便、潰瘍、食慾不振、體重減少等。

本報告提供克隆氏症治療藥的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

克隆氏症概要

治療藥的開發

克隆氏症:企業開發中的治療藥

克隆氏症:大學/機關研究中的治療藥

克隆氏症:開發中產品概況

克隆氏症:企業開發中的產品

克隆氏症:大學/機關研究中的產品

克隆氏症的治療藥開發企業

克隆氏症:治療藥的評估

藥物簡介

克隆氏症:最近的開發平台趨勢

克隆氏症:暫停中的計劃

克隆氏症:中止開發的產品

克隆氏症:產品開發的里程碑

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8354IDB

Summary

Global Markets Direct's, 'Crohn's Disease (Regional Enteritis) - Pipeline Review, H2 2016', provides an overview of the Crohn's Disease (Regional Enteritis) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Crohn's Disease (Regional Enteritis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Crohn's Disease (Regional Enteritis) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Crohn's Disease (Regional Enteritis)
  • The report reviews pipeline therapeutics for Crohn's Disease (Regional Enteritis) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Crohn's Disease (Regional Enteritis) therapeutics and enlists all their major and minor projects
  • The report assesses Crohn's Disease (Regional Enteritis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Crohn's Disease (Regional Enteritis)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Crohn's Disease (Regional Enteritis)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Crohn's Disease (Regional Enteritis) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • Crohn's Disease (Regional Enteritis) Overview
  • Therapeutics Development
  • Crohn's Disease (Regional Enteritis) - Therapeutics under Development by Companies
  • Crohn's Disease (Regional Enteritis) - Therapeutics under Investigation by Universities/Institutes
  • Crohn's Disease (Regional Enteritis) - Pipeline Products Glance
  • Crohn's Disease (Regional Enteritis) - Products under Development by Companies
  • Crohn's Disease (Regional Enteritis) - Products under Investigation by Universities/Institutes
  • Crohn's Disease (Regional Enteritis) - Companies Involved in Therapeutics Development
  • Crohn's Disease (Regional Enteritis) - Therapeutics Assessment
  • Drug Profiles
  • Crohn's Disease (Regional Enteritis) - Dormant Projects
  • Crohn's Disease (Regional Enteritis) - Discontinued Products
  • Crohn's Disease (Regional Enteritis) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Crohn's Disease (Regional Enteritis), H2 2016
  • Number of Products under Development for Crohn's Disease (Regional Enteritis) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Development by Companies, H2 2016 (Contd..6)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by 4D Pharma Plc, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by 4SC AG, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by AB Science SA, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by AbbVie Inc, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Alfa Wassermann S.p.A, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Alteogen Inc., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Amgen Inc., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Ampio Pharmaceuticals, Inc., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by ARA Healthcare Pvt. Ltd., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Arena Pharmaceuticals, Inc., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Astellas Pharma Inc., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by BioLingus AG, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Bionovis SA, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by BioTherapeutics Inc., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Calypso Biotech SA, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Celgene Corporation, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by ChemoCentryx, Inc., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by ChironWells GmbH, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by CLL Pharma, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Coherus BioSciences, Inc., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Commence Bio, Inc., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by DBV Technologies S.A., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Eisai Co., Ltd., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Eli Lilly and Company, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Enterome Bioscience SA, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Enzo Biochem, Inc., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Ferring International Center S.A., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Galapagos NV, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Genentech, Inc., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Genor BioPharma Co., Ltd., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Gilead Sciences, Inc., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by iCo Therapeutics Inc., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Idera Pharmaceuticals, Inc., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Immune Response BioPharma, Inc., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Innovent Biologics, Inc., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Johnson & Johnson, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Jyant Technologies, Inc., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Kang Stem Biotech Co., Ltd., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by KPI Therapeutics, Inc., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by MedImmune, LLC, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Merck & Co., Inc., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Mesoblast Limited, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Momenta Pharmaceuticals, Inc., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Mycenax Biotech Inc., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Neovacs SA, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Oncobiologics, Inc., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Oncodesign SA, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by OSE Immunotherapeutics, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Pfenex Inc., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Pfizer Inc., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Pieris Pharmaceuticals, Inc., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Pluristem Therapeutics Inc., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Protalix BioTherapeutics, Inc., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Qu Biologics Inc., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Re-Pharm Limited, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by RedHill Biopharma Ltd., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Sandoz International GmbH, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by SATT North SAS, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Second Genome, Inc., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Selexys Pharmaceuticals Corporation, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Selvita S.A., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Shire Plc, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Sigmoid Pharma Limited, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Soligenix, Inc., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Stelic Institute & Co., Inc., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Sylentis S.A.U., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by TaiwanJ Pharmaceuticals Co., Ltd., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Therapeutic Proteins International, LLC, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Tiziana Life Sciences Plc, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Trino Therapeutics Limited, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by TxCell SA, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Ventria Bioscience, H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Virobay Inc., H2 2016
  • Crohn's Disease (Regional Enteritis) - Pipeline by Xbrane Biopharma AB, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Crohn's Disease (Regional Enteritis) - Dormant Projects, H2 2016
  • Crohn's Disease (Regional Enteritis) - Dormant Projects (Contd..1), H2 2016
  • Crohn's Disease (Regional Enteritis) - Dormant Projects (Contd..2), H2 2016
  • Crohn's Disease (Regional Enteritis) - Dormant Projects (Contd..3), H2 2016
  • Crohn's Disease (Regional Enteritis) - Dormant Projects (Contd..4), H2 2016
  • Crohn's Disease (Regional Enteritis) - Dormant Projects (Contd..5), H2 2016
  • Crohn's Disease (Regional Enteritis) - Dormant Projects (Contd..6), H2 2016
  • Crohn's Disease (Regional Enteritis) - Dormant Projects (Contd..7), H2 2016
  • Crohn's Disease (Regional Enteritis) - Dormant Projects (Contd..8), H2 2016
  • Crohn's Disease (Regional Enteritis) - Dormant Projects (Contd..9), H2 2016
  • Crohn's Disease (Regional Enteritis) - Dormant Projects (Contd..10), H2 2016
  • Crohn's Disease (Regional Enteritis) - Dormant Projects (Contd..11), H2 2016
  • Crohn's Disease (Regional Enteritis) - Discontinued Products, H2 2016
  • Crohn's Disease (Regional Enteritis) - Discontinued Products (Contd..1), H2 2016

List of Figures

  • Number of Products under Development for Crohn's Disease (Regional Enteritis), H2 2016
  • Number of Products under Development for Crohn's Disease (Regional Enteritis) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top